Midori Isobe

Okayama University of Science — Japan

Immunology and Microbiology · Life Sciences

17h-index1.1kcitations85works1.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(54), Cancer Immunotherapy and Biomarkers(30), Monoclonal and Polyclonal Antibodies Research(26), T-cell and B-cell Immunology(17), vaccines and immunoinformatics approaches(12)

Publications85 total

Production of Short-lived Radionuclides Using a <sup>232</sup>Th/<sup>212</sup>Pb Generator from Naturally Occurring Radioactive Materials (NORM)—Application to the Safe Handling Training of Unsealed Radioisotopes—
RADIOISOTOPES·2025Open Access
Comparison of mutation spectra induced by gamma-rays and carbon ion beams
Journal of Radiation Research·2024· 3 citedOpen Access
Data from Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
2023Open Access
Supplementary Tables S1 through S9 from Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
2023Open Access
Supplementary Figures S1 through S6 from Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
2023Open Access
Supplementary Figures S1 through S6 from Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
2023Open Access
Supplementary Tables S1 through S9 from Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
2023Open Access
Data from Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
2023Open Access
Supplementary Figure 6 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 3 from Phase Ia Study of FoxP3<sup>+</sup> CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
2023Open Access
Supplementary Figure 3 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Data from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 4 from Phase Ia Study of FoxP3<sup>+</sup> CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
2023Open Access
Supplementary Figure 6 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 2 from Phase Ia Study of FoxP3<sup>+</sup> CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
2023Open Access
Data from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Figure 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
2023Open Access
Supplementary Table 3 from Phase Ia Study of FoxP3<sup>+</sup> CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
2023Open Access
Supplementary Figure 2 from Phase Ia Study of FoxP3<sup>+</sup> CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Eiichi Nakayama(41), Mikio Oka(34), Yoshihiro Ohue(32), Koji Kurose(29), Akiko Uenaka(25), Hisashi Wada(18), Yumi Nishio(16), Yu Mizote(16), Kazuhiro Kakimi(13), Minoru Fukuda(13), Hiroyoshi Nishikawa(11), Heiichiro Udono(10), Hirofumi Matsumoto(10), Ryuzo Ueda(8), Shingo Eikawa(8), Shinsuke Iida(7), Takashi Ishida(7), Toshihiko Doi(7), Takeru Funakoshi(7), Eiichi Sato(7)